What Is the Moderna mRNA Bird Flu Vaccine?
On April 21, 2026, Moderna dosed the first participants in a Phase 3 clinical trial for its mRNA-based H5 influenza vaccine candidate, mRNA-1018. This marks a historic milestone. For the first time, a pandemic bird flu vaccine built on mRNA technology has reached large-scale human testing.
Developed by Moderna, mRNA-1018 uses the same mRNA technology that underpinned its highly effective COVID-19 shot, adapted to target the A(H5N1) strain of bird flu. Unlike traditional seasonal flu vaccines, this candidate targets a specific pandemic threat. It is designed for stockpiling and rapid deployment — not routine annual use.
Why Did HHS Cancel Moderna’s Funding?
The Biden-Era Investment
Biden administration officials committed $176 million in summer 2024, then added $590 million in January 2025, as bird flu spread among livestock and occasional farmworkers. These funds flowed through BARDA — the Biomedical Advanced Research and Development Authority — which focuses on rapid development of medical treatments for public health emergencies.
The Trump Administration’s Reversal
Robert F. Kennedy Jr., a prominent skeptic of mRNA vaccines, took charge of HHS. The agency then directed $500 million in federal funding toward a different initiative called Generation Gold Standard, which uses alternative technology to develop universal shots against pandemic-prone viruses.
HHS Communications Director Andrew Nixon defended the move bluntly. He stated that after a rigorous review, the agency concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable, arguing mRNA technology remains under-tested.
U.S. Health Secretary Robert F. Kennedy Jr. ultimately canceled more than $700 million in Moderna bird flu vaccine contracts in May 2025. Nevertheless, Moderna pushed forward.
How CEPI Stepped In to Save the Trial
A Critical International Partnership
The Coalition for Epidemic Preparedness Innovations (CEPI) agreed to plug up to $54.3 million into a pivotal Phase 3 trial for mRNA-1018. This funding replaced the lost government support and kept the program alive.
CEPI’s CEO explained the broader mission clearly. Dr. Richard Hatchett said the partnership aims to harness the speed and adaptability of mRNA technology to shave months off pandemic response time, deliver vaccines at scale, and enable equitable global access.
Equity Built Into the Agreement
Importantly, CEPI tied a social commitment to the funding deal. As part of the partnership, Moderna has pledged that 20 percent of its H5 pandemic vaccine manufacturing capacity will be allocated for timely supply to low- and middle-income countries at affordable price levels if the vaccine is licensed.
What the Phase 3 Trial Involves
Scale, Sites, and Participants
The Phase 3 study of mRNA-1018 runs in the United States and the United Kingdom and expects to enroll about 4,000 healthy adults age 18 and older. Researchers are recruiting participants through community clinics rather than traditional hospital sites — a deliberate shift to bring vaccine research closer to where people live.
Priority Groups in the Study
Researchers are prioritizing recruitment of individuals over 65 and those working closely with poultry, as these groups face the highest risk of exposure to H5N1. Age-related immune changes and frequent contact with infected birds make both groups logical candidates for early testing.
The trial focuses on two primary goals: safety and immunogenicity. Researchers will monitor participants for side effects while measuring antibody and T-cell responses. Results will then inform whether mRNA-1018 meets FDA and EMA thresholds for emergency use or full licensure.
What Early Trial Data Shows
Strong Phase 1/2 Results
Moderna did not enter Phase 3 blindly. The Phase 1/2 study enrolled approximately 300 healthy adults. Only 2.1% of participants showed pre-existing immunity at baseline. By day 43 — three weeks after the second dose — 97.8% of participants achieved protective antibody titers, representing a 44.5-fold increase from baseline.
Tolerability and Safety Profile
The vaccine was well-tolerated among a majority of the study population, with minimal adverse reactions and no increases in these events as doses increased. These results gave Moderna the confidence to proceed without federal backing.
CEO Stéphane Bancel noted that the termination of HHS funding adds uncertainty but added that the robust immune response and strong safety profile from the interim Phase 1/2 analysis justified exploring alternative paths forward.
Why Experts Are Alarmed by the Funding Cut
Public Health Voices Push Back
The scientific community reacted sharply to HHS’s decision. Ashish Jha, dean of the Brown University School of Public Health, said the vaccine contract cancellation puts American lives at risk, and called the attack on mRNA vaccines absurd given their widely studied safety and effectiveness track record.
Former BARDA chief Rick Bright was equally direct. He called the HHS decision a huge mistake, warning that mRNA vaccines can be produced far faster than traditional egg-based or cell-based alternatives — and that speed matters in a rapidly expanding pandemic.
The Speed Advantage at Stake
Dr. Bruce Gellin, a vaccine program director under two presidents, warned that losing the capability to respond quickly would allow future deaths that could otherwise be prevented, and cautioned that a decision treating speed as unimportant could prove catastrophic.
What Comes Next for Pandemic Preparedness
The Current H5N1 Threat Level
Today, the public health risk remains contained but real. The CDC says A(H5) bird flu is widespread in wild birds globally and is causing outbreaks in poultry and U.S. dairy cows, with sporadic human cases among dairy and poultry workers. As of March 6, 2026, the agency reported 71 human cases in the United States since February 2024, including 2 deaths, with exposures mainly linked to dairy herds and poultry farms or culling operations.
Regulatory Pathway Forward
If successful, global regulatory submissions for mRNA-1018 will be further supported by positive data from the pivotal Phase 3 trial of Moderna’s investigational seasonal influenza vaccine, mRNA-1010, which has already been accepted for review in the U.S., the European Union, Canada, and Australia.
A Defining Moment for mRNA Technology
This trial is more than a product launch. It is a test of whether mRNA-based pandemic preparedness can survive political headwinds. Furthermore, it signals a broader shift in global health funding — away from sole reliance on U.S. government contracts and toward international coalitions like CEPI. As H5N1 continues to evolve, the outcome of this Phase 3 trial could determine how quickly the world responds if the virus ever achieves efficient human-to-human spread.
